01:56 PM EST, 12/09/2025 (MT Newswires) -- Opus Genetics ( IRD ) said Tuesday the independent data monitoring committee overseeing a phase 1/2 trial of OPGx-BEST1 in patients with Best disease has completed its safety review and recommended proceeding with enrollment and dosing of additional participants as planned.

The committee reviewed one-month data from the sentinel participant and found OPGx-BEST1 to have an initial favorable safety profile, the company said.

The dose-exploring study is evaluating OPGx-BEST1 in participants with Best disease, or vitelliform macular dystrophy, a rare inherited retinal condition.

Shares of the company were up more than 6% in recent trading Tuesday.

Price: 2.44, Change: +0.15, Percent Change: +6.33